BALAXI.NS Stock Analysis
BA
Uncovered
Balaxi Pharmaceuticals Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Balaxi Pharmaceuticals Ltd. engages in the exportation of pharmaceutical, hardware, and FMCG products. The company is headquartered in Hyderabad, Telangana and currently employs 51 full-time employees. The company went IPO on 2015-11-30. The firm is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. The company has a portfolio across multiple therapeutic segments, stock & sell models, and supplying branded and generic medicines. The firm is offerings more than 300 products across multiple therapeutic areas, including Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhoea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its consumer products include Nice 45 G, Guloso 45 G, Snax! 42 G, Doce E Sal 42 G, Yumm 75 G and Boadent.